144 related articles for article (PubMed ID: 25672738)
1. [Development of disease modifying drugs for dementia-focusing on anti-tau drugs-].
Soeda Y; Takashima A
Rinsho Shinkeigaku; 2014; 54(12):1178-80. PubMed ID: 25672738
[TBL] [Abstract][Full Text] [Related]
2. [Contribution of molecular imaging research to innovative drug development].
Shimada H
Rinsho Shinkeigaku; 2014; 54(12):1174-7. PubMed ID: 25672737
[TBL] [Abstract][Full Text] [Related]
3. [Alzheimer's disease: from brain lesions to new drugs].
Forette F; Hauw JJ
Bull Acad Natl Med; 2008 Feb; 192(2):363-78; discussion 378-80. PubMed ID: 18819689
[TBL] [Abstract][Full Text] [Related]
4. [Therapy of Alzheimer disease].
Kovács T
Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
[TBL] [Abstract][Full Text] [Related]
5. [Prion-like Propagation Model of Tau].
Hosokawa M; Hasegawa M
Yakugaku Zasshi; 2019; 139(7):1021-1025. PubMed ID: 31257249
[TBL] [Abstract][Full Text] [Related]
6. [Antidementia drugs].
Müller-Spahn F; Sollberger D; Wollmer MA
Ther Umsch; 2009 Jun; 66(6):432-40. PubMed ID: 19496039
[TBL] [Abstract][Full Text] [Related]
7. Drug therapy of frontotemporal dementia.
Allain H; Bentué-Ferrer D; Tribut O; Mérienne M; Belliard S
Hum Psychopharmacol; 2003 Apr; 18(3):221-5. PubMed ID: 12672175
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of tau aggregation in a novel Caenorhabditis elegans model of tauopathy mitigates proteotoxicity.
Fatouros C; Pir GJ; Biernat J; Koushika SP; Mandelkow E; Mandelkow EM; Schmidt E; Baumeister R
Hum Mol Genet; 2012 Aug; 21(16):3587-603. PubMed ID: 22611162
[TBL] [Abstract][Full Text] [Related]
9. Dysregulation of tau phosphorylation is a hypothesized point of convergence in the pathogenesis of alzheimer's disease, frontotemporal dementia and schizophrenia with therapeutic implications.
Deutsch SI; Rosse RB; Lakshman RM
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Dec; 30(8):1369-80. PubMed ID: 16793187
[TBL] [Abstract][Full Text] [Related]
10. [Drug development for tauopathy and Alzheimer's disease].
Takashima A
Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Aug; 30(4):177-80. PubMed ID: 20857696
[TBL] [Abstract][Full Text] [Related]
11. [Diagnosis and treatment of dementia: overview].
Furukawa K; Ishiki A; Tomita N; Arai H
Rinsho Shinkeigaku; 2014; 54(12):1171-3. PubMed ID: 25672736
[TBL] [Abstract][Full Text] [Related]
12. Effects of tau domain-specific antibodies and intravenous immunoglobulin on tau aggregation and aggregate degradation.
Esteves-Villanueva JO; Trzeciakiewicz H; Loeffler DA; Martić S
Biochemistry; 2015 Jan; 54(2):293-302. PubMed ID: 25545358
[TBL] [Abstract][Full Text] [Related]
13. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O
Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011
[TBL] [Abstract][Full Text] [Related]
14. Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons.
Padmanabhan J; Levy M; Dickson DW; Potter H
Brain; 2006 Nov; 129(Pt 11):3020-34. PubMed ID: 16987932
[TBL] [Abstract][Full Text] [Related]
15. Novel tubulin and tau neuroprotective fragments sharing structural similarities with the drug candidate NAP (Davuentide).
Gozes I; Iram T; Maryanovsky E; Arviv C; Rozenberg L; Schirer Y; Giladi E; Furman-Assaf S
J Alzheimers Dis; 2014; 40 Suppl 1():S23-36. PubMed ID: 24503616
[TBL] [Abstract][Full Text] [Related]
16. New perspectives on the role of tau in Alzheimer's disease. Implications for therapy.
Medina M; Avila J
Biochem Pharmacol; 2014 Apr; 88(4):540-7. PubMed ID: 24462919
[TBL] [Abstract][Full Text] [Related]
17. Histopathological changes underlying frontotemporal lobar degeneration with clinicopathological correlation.
Shi J; Shaw CL; Du Plessis D; Richardson AM; Bailey KL; Julien C; Stopford C; Thompson J; Varma A; Craufurd D; Tian J; Pickering-Brown S; Neary D; Snowden JS; Mann DM
Acta Neuropathol; 2005 Nov; 110(5):501-12. PubMed ID: 16222525
[TBL] [Abstract][Full Text] [Related]
18. [Nootropic drugs and their action mechanisms in relation to the neuropathobiology of senile dementia. I. Neurotransmission disorders in the brain].
Benesová O
Cesk Psychiatr; 1994 Aug; 90(4):191-200. PubMed ID: 7987928
[TBL] [Abstract][Full Text] [Related]
19. The novel calpain inhibitor A-705253 prevents stress-induced tau hyperphosphorylation in vitro and in vivo.
Nikkel AL; Martino B; Markosyan S; Brederson JD; Medeiros R; Moeller A; Bitner RS
Neuropharmacology; 2012 Sep; 63(4):606-12. PubMed ID: 22613839
[TBL] [Abstract][Full Text] [Related]
20. [Tau story: from frontotemporal dementia to other tauopathies].
Buée L; Hamdane M; Delobel P; Sambo AV; Bégard S; Ghestem A; Sergeant N; Delacourte A
J Soc Biol; 2002; 196(1):103-8. PubMed ID: 12134624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
